Sign InBreakout Stocks of Week 22 @ NASDAQ
NASDAQ was up last week (week 21) by 0.453% ending at 26,343.97 points after gaining 118.83 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Masimo Corporation NASDAQ:MASI. This stock has had a buy signal since Feb 19, 2026 when the price was $175.33 and is so far up 1.98% to $178.81. Some other companies are on our watchlist to, among these are Aquestive Therapeutics Inc. NASDAQ:AQST Lesaka Technologies, Inc. NASDAQ:LSAK Icahn Enterprises L.P. NASDAQ:IEP and Petco Health and Wellness Company, Inc. NASDAQ:WOOF which all got a breakout pattern emerging.
| Date | Company | Price | Week 22 |
|---|---|---|---|
| Masimo Corporation | $178.81 | $178.45 | -0.201% |
| Aquestive Therapeutics Inc. | $4.12 | $4.02 | -2.43% |
| Lesaka Technologies, Inc. | $4.94 | $4.89 | -1.01% |
| Icahn Enterprises L.p. | $7.55 | $7.44 | -1.46% |
| Petco Health And Wellness Company, Inc. | $2.65 | $3.01 | 13.58% |
The Masimo Corporation stock price gained 0.0952% on the last trading day (Friday, 22nd May 2026), rising from $178.64 to $178.81. During the last trading day the stock fluctuated 0.272% from a day low at $178.36 to a day high of $178.84. The price has risen in 5 of the last 10 days and is up by 0.28% over the past 2 weeks. Volume fell on the last day by -506 thousand shares and in total, 671 thousand shares were bought and sold for approximately $120.00 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
On Mar 27, 2026, it was reported that Raymond James gave MASI a "Market Perform" grade with a "downgrade" action.
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Masimo Corporation stock to perform well in the short-term.
About Masimo Corporation:
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
The Aquestive Therapeutics Inc. stock price fell by -2.60% on the last day (Friday, 22nd May 2026) from $4.23 to $4.12. During the last trading day the stock fluctuated 4.25% from a day low at $4.12 to a day high of $4.29. The price has fallen in 6 of the last 10 days and is down by -4.63% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -447 thousand shares and in total, 888 thousand shares were bought and sold for approximately $3.66 million.
On Feb 02, 2026, it was reported that Oppenheimer gave AQST a "Outperform" grade with a "hold" action.
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Aquestive Therapeutics Inc. stock to perform well in the short-term.
About Aquestive Therapeutics Inc.:
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
The Lesaka Technologies, Inc. stock price fell by -1.00% on the last day (Friday, 22nd May 2026) from $4.99 to $4.94. During the last trading day the stock fluctuated 2.66% from a day low at $4.89 to a day high of $5.02. The price has fallen in 6 of the last 10 days but is still up by 1.65% over the past 2 weeks. Volume has increased on the last day by 676 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 799 thousand shares were bought and sold for approximately $3.95 million.
On May 26, 2026, it was reported that Investec gave LSAK a "Hold" grade with a "initialise" action.
Lesaka Technologies, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
The Icahn Enterprises stock price gained 0.266% on the last trading day (Friday, 22nd May 2026), rising from $7.53 to $7.55. During the last trading day the stock fluctuated 1.07% from a day low at $7.50 to a day high of $7.58. The price has risen in 6 of the last 10 days but is still down by -5.86% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 736 thousand more shares were traded than the day before. In total, 1 million shares were bought and sold for approximately $10.41 million.
Icahn Enterprises holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Icahn Enterprises L.P.:
Icahn Enterprises L.P., through its subsidiaries, operates in investment, energy, automotive, food packaging, real estate, home fashion, and pharma businesses in the United States and Internationally. Its Investment segment invests its proprietary capital through various private investment funds. The company's Energy segment refines and markets transportation fuels; and produces and markets nitrogen fertilizers in the form of urea ammonium nitrate and ammonia. Its Automotive segment is involved in the retail and wholesale distribution of automotive parts; and offers automotive repair and maintenance services. The company's Food Packaging segment produces and sells cellulosic, fibrous, and plastic casings that are used for preparing processed meat products. Its Real Estate segment is involved in the rental of retail, office, and industrial properties; construction and sale of single-family homes and residential units; and golf and club operations. This segment also engages in hotel and timeshare resort operations. The company's Home Fashion segment manufactures, sources, markets, distributes, and sells home fashion consumer products. Its Pharma segment offers pharmaceutical products and services. The company was incorporated in 1987 and is headquartered in Sunny Isles Beach, Florida.
No changes to the price of Petco Health and Wellness Company, Inc. stock on the last trading day (Friday, 22nd May 2026). During the last trading day the stock fluctuated 2.84% from a day low at $2.64 to a day high of $2.72. The price has risen in 5 of the last 10 days but is still down by -5.69% for this period.
On Jun 05, 2026, it was reported that Goldman Sachs gave WOOF a "Neutral" grade with a "hold" action.
Petco Health and Wellness Company, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Petco Health and Wellness Company, Inc.:
Petco Health and Wellness Company, Inc., a health and wellness company, focuses on enhancing the lives of pets, pet parents, and its Petco partners. The company provides veterinary care, grooming, training, tele-health, and Vital Care and pet health insurance services, as well as veterinary services through Vetco mobile clinics. It also offers pet consumables, supplies, and services through its petco.com, petcoach.co, petinsurancequotes.com, and pupbox.com websites. As of March 23, 2022, the company operated approximately 1,500 Petco locations in the United States, Mexico, and Puerto Rico that included a network of approximately 200 in-store veterinary hospitals. Petco Health and Wellness Company, Inc. was founded in 1965 and is headquartered in San Diego, California.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
RUN
$12.83
|
4.09% | May 06 |
GLBE
$31.61
|
1.65% | May 05 |
SAP
$172.39
|
7.18% | May 05 |
FIZZ
$34.11
|
7.04% | May 01 |
ADBE
$243.57
|
3.23% | Apr 29 |
